CL2009000257A1 - Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome. - Google Patents

Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome.

Info

Publication number
CL2009000257A1
CL2009000257A1 CL2009000257A CL2009000257A CL2009000257A1 CL 2009000257 A1 CL2009000257 A1 CL 2009000257A1 CL 2009000257 A CL2009000257 A CL 2009000257A CL 2009000257 A CL2009000257 A CL 2009000257A CL 2009000257 A1 CL2009000257 A1 CL 2009000257A1
Authority
CL
Chile
Prior art keywords
treatment
metabolic syndrome
physiologically compatible
compatible salts
substituted imidazolines
Prior art date
Application number
CL2009000257A
Other languages
Spanish (es)
Inventor
Gerhard Jaehne
Antony Bigot
Siegfried Stengelin
Matthias Gossel
Irvin Winkler
Anita Diu-Hercend
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000257A1 publication Critical patent/CL2009000257A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de imidazolinas 1,3 sustituidas y de sus sales fisiológicamente compatibles para el tratamiento del síndrome metabólico.Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome.

CL2009000257A 2008-02-07 2009-02-05 Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome. CL2009000257A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290132 2008-02-07

Publications (1)

Publication Number Publication Date
CL2009000257A1 true CL2009000257A1 (en) 2009-06-26

Family

ID=39502138

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000257A CL2009000257A1 (en) 2008-02-07 2009-02-05 Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome.

Country Status (5)

Country Link
AR (1) AR071345A1 (en)
CL (1) CL2009000257A1 (en)
TW (1) TW200946114A (en)
UY (1) UY31646A1 (en)
WO (1) WO2009097996A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
EA201791982A1 (en) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY
MX2019008535A (en) * 2017-01-18 2019-12-02 Coherus Biosciences Inc Pparï’ agonist for the treatment of huntington's disease.
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
CN112759550A (en) * 2019-11-04 2021-05-07 上海科技大学 Smooth receptor antagonist
CN113024513A (en) * 2021-03-22 2021-06-25 中国药科大学 Novel androgen receptor degradation agent, preparation method and medical application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (en) * 1992-07-08 1994-09-02 Roussel Uclaf New substituted phenylimidazolidines, process for their preparation, their use as medicaments and the pharmaceutical compositions containing them.

Also Published As

Publication number Publication date
TW200946114A (en) 2009-11-16
UY31646A1 (en) 2009-08-31
WO2009097996A1 (en) 2009-08-13
AR071345A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CL2016002589A1 (en) Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
CY1120741T1 (en) TREATMENT OF NOSE SCRUB
CL2015002194A1 (en) Erk inhibitors and their uses
CL2015000942A1 (en) Compounds of substituted benzene.
CL2008002042A1 (en) Compounds derived from linked nitrogenous heterocycles; and its use in the treatment of diabetes and metabolic disorders.
CL2011000454A1 (en) Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CL2008003284A1 (en) Compounds derived from 4-benzylamino-1-carboxyacyl-pyridine, cetp inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; and use in the treatment of metabolic, atherosclerosis and cardiovascular diseases, among others.
CL2008002097A1 (en) Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer.
NI201200072A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
CL2012002189A1 (en) Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
ES2488407T3 (en) Pharmaceutical preparation containing lipase of bacterial origin
CL2008002006A1 (en) Compounds derived from morpholin pyrimidine, pharmaceutical composition, and their use as inhibitors of m-tor-kinase for the treatment of inflammation, cancer, immune diseases, obstructive pulmonary disease, cardiovascular disease.
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
EA201000888A1 (en) 4-PHENYPYRANE-3,5-DIONES, 4-PHENYLTYOPYRANE-3,5-DIONS AND 2-PHENYLCYCLOGEXAN-1,3,5-TRIONS AS HERBICIDES
CL2009000402A1 (en) Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.
CL2008001024A1 (en) Phthalazinone derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cardiovascular diseases, parkinson's, inflammatory diseases, multiple sclerosis, cancer, among others
ATE530170T1 (en) PALIPERIDONE SUSTAINED RELEASE FORMULATION
CL2008000110A1 (en) USE OF COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED FOR THE TREATMENT OF METABOLIC SYNDROME; AND COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED.
CL2009000119A1 (en) Compounds derived from substituted amino-benzimidazoles; pharmaceutical composition; and its use in the treatment of Alzheimer's.
ECSP11011021A (en) ANTAGONISTS OF THE VIA HEDGEHOG OF FTALAZINA DISUSTITUIDA
CL2009000257A1 (en) Use of 1,3-substituted imidazolines and their physiologically compatible salts for the treatment of metabolic syndrome.
CL2008002545A1 (en) Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
CL2008001795A1 (en) USE OF AN ANTAGONIST PAR1 IN THE TREATMENT OF ATRIAL FIBRILATION.